{"id":799,"date":"2025-11-17T11:34:29","date_gmt":"2025-11-17T11:34:29","guid":{"rendered":"https:\/\/chromocan.test\/service\/custom-purification\/"},"modified":"2026-05-07T14:08:53","modified_gmt":"2026-05-07T12:08:53","slug":"custom-purification","status":"publish","type":"service","link":"https:\/\/www.chromacon.com\/en\/services\/custom-purification\/","title":{"rendered":"Custom Purification"},"content":{"rendered":"
\n
\n
\n
\n
\n
\n

\n CUSTOM PURIFICATION <\/p>\n \n

\n Outsource your Purification\n <\/h1>\n \n
\n

Custom purification services. When you need purified material \u2014 but not the equipment, the method, or the timeline cost of building one in-house. We deliver purified fractions from your starting material at our Zurich facility, with full analytical data.<\/p>\n <\/div>\n <\/div>\n\n

\n
\n Talk to an Expert<\/span><\/a><\/span> <\/div>\n <\/div>\n <\/div>\n <\/div>\n\n
\n
\n
\n \"\" <\/div>\n\n
\n \"\" <\/div>\n \n
\n
\n Talk to an Expert<\/span><\/a><\/span> <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n
<\/div>\n <\/section>\n\n
\n \n
\n
\n
\n

\n Preparative Separations You Can't Do In-House <\/h2>\n \n
\n

Isolating individual protein variants from complex biopharmaceutical mixtures is one of the hardest challenges in downstream processing. Whether you need charge isoforms separated by ion exchange or size variants isolated by SEC, analytical methods rarely translate to preparative scale \u2014 and most labs lack the specialised equipment, resins, and expertise to bridge that gap.<\/p>\n

YMC ChromaCon<\/strong> provides fully customised purification services for monoclonal antibodies, fusion proteins, peptide hormones, and other biotherapeutics. Every project is scoped to your molecule, your target fractions, and your quality requirements \u2014 from initial method feasibility through to formulated, ready-to-use material.<\/p>\n

Our in-house services are available to pharmaceutical and biotechnology companies across Europe. Customers outside Europe can access purification services through our regional distribution partners.<\/p>\n <\/div>\n \n <\/div>\n\n

\n \"\" \n <\/div>\n <\/div>\n <\/section>\n\n<\/section>\n\n
\n \n
\n
\n
\n

\n Separation Challenges We Solve <\/h2>\n \n
\n
Charge variant fractionation<\/strong><\/h5>\n

Isolation of acidic, main, and basic isoform fractions from monoclonal antibodies and fusion proteins using preparative ion exchange chromatography (SCX, WAX, SAX). Whether your chromatogram shows 3 peaks or 12+, we develop a method matched to your resolution requirements.<\/p>\n

Size variant fractionation<\/strong><\/h5>\n

Separation of high molecular weight (HMW), monomer (main), and low molecular weight (LMW) fractions using preparative size exclusion chromatography (SEC). Ideal for producing analytical reference standards from native or stressed starting materials.<\/p>\n

Peptide and protein isoform isolation<\/strong><\/h5>\n

Purification of low-abundance target isoforms from complex feed mixtures \u2014 including cases where the target represents only a few percent of total protein.<\/p>\n

Analytical method development<\/strong><\/h5>\n

Where needed, we develop or optimise analytical HPLC methods alongside the preparative work, so fraction identity and purity can be confirmed throughout the project.<\/p>\n <\/div>\n \n <\/div>\n\n

\n \"\" \n <\/div>\n <\/div>\n <\/section>\n\n<\/div><\/section>\n\n
\n \n
\n
\n
\n

\n Flexible Project Structure With Built-In Decision Points <\/h2>\n \n
\n

Depending on the complexity of your separation, your project may include two or three phases \u2014 each ending with a clear go\/no-go decision point.<\/p>\n

Typical project structures:<\/strong><\/p>\n

\n\n\n\n\n\n\n\n
Separation complexity<\/th>\nPhases<\/th>\nTypical duration<\/th>\n<\/tr>\n<\/thead>\n
Well-characterised molecule, known chromatography mode<\/td>\nFeasibility + Production<\/td>\n6\u201312 weeks<\/td>\n<\/tr>\n
Novel molecule or poor analytical resolution<\/td>\nScreening + Feasibility + Production<\/td>\n8\u201320 weeks<\/td>\n<\/tr>\n
Method transfer or small-scale production<\/td>\nProduction only (by agreement)<\/td>\n2\u20138 weeks<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

You review results and approve each transition. If the science doesn’t support moving forward, you stop \u2014 with full transparency on what was learned.<\/p>\n <\/div>\n \n <\/div>\n\n <\/div>\n <\/section>\n\n<\/section>\n\n

\n \n
\n
\n
\n

\n Project Phases at a Glance <\/h2>\n \n
\n \ufeff<\/span><\/p>\n\n\n\n\n\n\n\n
<\/th>\nScreening (optional)<\/th>\nFeasibility & Method Dev<\/th>\nProduction & Delivery<\/th>\n<\/tr>\n<\/thead>\n
Goal<\/strong><\/td>\nIdentify best resin, buffer, and mode<\/td>\nOptimise method; define fractions<\/td>\nProduce target quantities<\/td>\n<\/tr>\n
Key activities<\/strong><\/td>\nMulti-resin\/buffer screening, initial loading<\/td>\nLoading studies, gradient optimisation, fraction analysis<\/td>\nPreparative runs, concentration, formulation, shipping<\/td>\n<\/tr>\n
Deliverables<\/strong><\/td>\nFeasibility report, screening samples<\/td>\nOptimised method, quantity\/purity estimates<\/td>\nPurified fractions, analytical certificates, final report<\/td>\n<\/tr>\n
Decision point<\/strong><\/td>\nGo \/ No-go before development<\/td>\nJoint review before production<\/td>\n\u2014<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n <\/div>\n \n <\/div>\n\n
\n \"\" \n <\/div>\n <\/div>\n <\/section>\n\n<\/div><\/section>\n\n
\n
\n

Project Phase Details:<\/h2>\n

Depending on the complexity of your separation, your project may include two or three phases \u2014 each ending with a clear go\/no-go decision point.<\/p>\n<\/div>\n <\/div>\n \n

\n \n